

CITATION REPORT

List of articles citing

Initial combination therapy of macitentan and tadalafil
in pulmonary arterial hypertension

DOI: 10.1183/13993003.00673-2020

European Respiratory Journal, 2020, 56, .

Source: <https://exaly.com/paper-pdf/76574289/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
23	Time Is of the Essence in PAH Therapy. <i>Chest</i> , 2021 , 160, 25-26	5.3	
22	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. <i>Chest</i> , 2021 , 160, 277-286	5.3	4
21	Topic-Based, Recent Literature Review on Pulmonary Hypertension. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 3109-3121	6.4	1
20	Sudden Cardiac Death in Systemic Sclerosis: Diagnostics to Assess Risk and Inform Management. <i>Diagnostics</i> , 2021 , 11,	3.8	0
19	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1393-1403	15.1	16
18	Strategies for the management of pulmonary arterial hypertension in patients with congenital heart disease. <i>Journal of Congenital Cardiology</i> , 2020 , 4,	1	0
17	Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial.. <i>Journal of Heart and Lung Transplantation</i> , 2022 ,	5.8	0
16	Pulmonary arterial hypertension in hereditary hemorrhagic telangiectasia associated with ACVRL1 mutation: a case report.. <i>Journal of Medical Case Reports</i> , 2022 , 16, 99	1.2	0
15	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	2
14	Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 843606	5.4	0
13	Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?. <i>Respiratory Medicine and Research</i> , 2022 , 81, 100893	1.4	
12	Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan. <i>JACC Asia</i> , 2022 , 2, 273-284		0
11	To be or not to be treated with initial combination therapy, that is the (PAH) question. <i>European Respiratory Journal</i> , 2022 , 59, 2200390	13.6	
10	Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension. <i>Open Heart</i> , 2022 , 9, e002054	3	
9	Mixed venous oxygen tension is a crucial prognostic factor in pulmonary hypertension: a retrospective cohort study. 2022 , 22,		
8	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
7	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58

- 6 Haemodynamic effects of initial combination therapy in pulmonary arterial hypertension: a systematic review and meta-analysis. 00313-2022 o
- 5 Early echocardiographic evaluation of right ventricular load adaptability after sequential combination treatment in pulmonary arterial hypertension. o
- 4 Nanomedicine-based treatment: An emerging therapeutical strategy for pulmonary hypertension. o
- 3 Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD). **2023**, 13, o
- 2 Advances in the discovery of drugs that treat pulmonary arterial hypertension. **2023**, 18, 445-466 o
- 1 Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. **2023**, 12, o